Clinical trials: Neoplasia Prostate
Metastatic Castration Resistant Prostate Cancer
Observational Study on Lutetium (177Lu) Vipivotide Tetraxetan to Treat Metastatic Castration Resistant Prostate Cancer
This is a local prospective, multicenter, long-term, non-interventional study using primary data collection to describe the routine clinical practice of patients with mCRPC treated with lutetium (177Lu) vipivotide tetraxetan.
- Trial name
- NCT07093801
- Where
- 35 sites in Italy
- Volunteers
- 300 people
- Sponsor
- Novartis Pharmaceuticals
Head & Neck Cancer, Pancreas Carcinoma
SL-28 for Advanced Solid Tumours
Second Life Therapeutics is developing SL-28, an allogeneic, non-genetically modified cell-based therapy for the treatment of advanced solid tumours.
- Conditions
- Head & Neck Cancer, Pancreas Carcinoma, Pancreas Cancer, Metastatic, Lung Adenocarcinoma
- Trial name
- NCT07341737
- Testing
- SL-28
- Where
- 3 sites in Australia
- Volunteers
- 60 people
- Sponsor
- Second Life Therapeutics
Prostate Cancer
The TRANSLATE Trial
The TRANSLATE randomised controlled trial aims to evaluate local anaesthetic transperineal biopsy (LATP) versus transrectal ultrasound-guided (TRUS) prostate biopsy, in the evaluation of previously biopsy-naive men being…
- Trial name
- TRANSLATE (NCT05179694)
- Testing
- Prostate biopsy
- Where
- United Kingdom
- Volunteers
- 1,042 people
- Sponsor
- University of Oxford
Malignancy
Application of 18F-PSMA PET / CT Imaging in Prostate Specific Membrane Antigen Positive Tumor
In this study, Al18F-PSMA-BCH PET/CT will be performed in patients with prostate specific membrane antigen positive tumor, to evaluate the tumour detection efficacy of Al18F-PSMA-BCH PET/CT.
- Trial name
- NCT05761366
- Testing
- Al18F-PSMA-BCH PET/CT
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Healthy Men Age 50 Who Are Considering PSA Screening
Decision Support Interventions (DESI) for Prostate Cancer Screening - Study 1
In this study we will compare 3 strategies for systematic delivery of prostate cancer screening decision support interventions (DESI) to usual care and examine their impact on screening decisions and subsequent healthcare…
- Trial name
- NCT01241656
- Testing
- DESI for home viewing, DESI for viewing at Shared Medical Appointment, Option of SMA and DESI or DESI only
- Where
- 2 sites in United States
- Volunteers
- 2,521 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant
Evaluating the Clinical Accuracy of Gallium-68 PSMA PET/CT Imaging in Patients With Biochemical Recurrence of Prostate Cancer
This study investigates if a new drug (PSMA) makes prostate cancer easier to identify in positron-emission tomography (PET) imaging.
- Trial name
- NCT03822845
- Testing
- Ga-68 PSMA-HBED-CC PET
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Michael Graham PhD, MD
Prostate Cancer
A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases
This research study is being done to measure the clinical benefit associated with cabozantinib (XL184) in men who have prostate cancer that has spread to visceral organs (organs other than bone or lymph nodes) and no longer…
- Trial name
- NCT01834651
- Testing
- Cabozantinib
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Edwin Posadas, MD
Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer
This phase II trial evaluates the best duration for relugolix to be given in combination with radiation therapy when treating patients with high risk prostate cancer. Prostate cancer is a hormonal influenced cancer.
- Conditions
- Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
- Trial name
- NCT06129851
- Testing
- Biospecimen Collection, Bone Scan, Brachytherapy
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- University of Kansas Medical Center
Urinary Incontinence
Predictor of Early Recovery on Urinary Continence After Laparoscopic Radical Prostatectomy
To investigate the relationship between post-operative bladder neck levels and urodynamic parameters and their effect on urinary incontinence after laparoscopic radical prostatectomy (LRP).
- Trial name
- NCT03097367
- Testing
- bladder neck level on cystography
- Volunteers
- 48 people
- Sponsor
- Buddhist Tzu Chi General Hospital
Breast Cancer, Lung Cancer
A Novel Approach for Alleviating the Side Effects of Chemotherapeutic Agents.
This study will assess the effectiveness of a natural nutraceutical in treating the known side effects of chemotherapeutic agents in cancer patients.
- Conditions
- Breast Cancer, Lung Cancer, Prostate Cancer
- Trial name
- NCT05137067
- Testing
- Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus Dietary Supplement (RaproCell), Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel).
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Optimal Health Research
Hormone-refractory Prostate Cancer, Adenocarcinoma of the Prostate
Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer
The purpose of this research study is to find out if a new anti-cancer drug, dasatinib (Sprycel®), previously approved for treatment of some forms of leukemia, will be safe and helpful in treating patients with hormone-refractory…
- Conditions
- Hormone-refractory Prostate Cancer, Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Prostate Cancer
- Trial name
- NCT00570700
- Testing
- Dasatinib
- Where
- 6 sites in United States
- Volunteers
- 38 people
- Sponsor
- University of California, Irvine
Hormone-refractory Prostate Cancer
Study of ILX651 in Patients With Hormone-Refractory Prostate Cancer Previously Treated With Docetaxel
This is a Phase II, non-randomized, open label study of ILX651 in patients with hormone-refractory prostate cancer previously treated with docetaxel.
- Trial name
- NCT00082134
- Testing
- ILX651
- Where
- 12 sites in United States
- Volunteers
- 40 people
- Sponsor
- Genzyme, a Sanofi Company
Breast Cancer, NSCLC
Docetaxel Ethanol-induced Symptoms; The Incidence and Risk Forecating Factor
To determine the incidence and risk factors of ethanol-induced symptoms, this multicenter, prospective, observational study is designed to include patients in Korea who are receiving chemotherapy with ethanol-containing docetaxel…
- Conditions
- Breast Cancer, NSCLC, Prostate Cancer, Head and Neck Cancer
- Trial name
- DETECT (NCT04545632)
- Where
- South Korea
- Volunteers
- 458 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Castration Levels of Testosterone, Hormone-Resistant Prostate Cancer
Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
This phase II trial studies how well durvalumab works in treating patients with prostate cancer that is resistant to hormones and has spread to other places in the body.
- Conditions
- Castration Levels of Testosterone, Hormone-Resistant Prostate Cancer, Microsatellite Instability
- Trial name
- NCT02966587
- Testing
- Durvalumab, Laboratory Biomarker Analysis
- Where
- United States
- Sponsor
- University of Washington
Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma
Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies
In this study, patients who have metastatic prostate cancer that does not respond to hormone treatment and who have mutations in certain cancer-related genes will be treated with docetaxel and carboplatin chemotherapy.
- Conditions
- Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
- Trial name
- NCT02985021
- Testing
- Carboplatin, Docetaxel
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- Seattle Institute for Biomedical and Clinical Research
Biochemically Recurrent Prostate Cancer
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies
Researchers are looking for a better way to treat men at high-risk of biochemical recurrence (BCR) of prostate cancer. BCR means that in men who had prostate cancer and were treated by either surgery and/ or radiation therapy…
- Trial name
- ARASTEP (NCT05794906)
- Testing
- Darolutamide (BAY1841788, Nubeqa), ADT
- Where
- 226 sites in United States, Australia and 21 more
- Volunteers
- 985 people
- Sponsor
- Bayer
Prostate Cancer
68Ga-NTA-476 Imaging in Prostate Cancer
This study is investigating a new agent to be used in PET imaging for prostate cancer, called 68Ga-NTA-476. It aims to find out where 68Ga-NTA-476 goes in the body once it is injected into a person and whether there are any side…
- Trial name
- NTA-476 (NCT06520449)
- Testing
- 68Ga-NTA-476
- Where
- Australia
- Volunteers
- 10 people
- Sponsor
- Melbourne Theranostic Innovation Centre
Genitourinary Cancer, Adrenocortical Carcinoma
Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
This research study is studying a combination of drugs as a possible treatment for rare genitourinary malignancies among four cohorts, bladder or upper tract carcinoma with variant histology, adrenocortical carcinoma, other rare…
- Conditions
- Genitourinary Cancer, Adrenocortical Carcinoma, Non-urothelial Bladder, Non-urothelial Upper Tract
- Trial name
- NCT03333616
- Testing
- Ipilimumab, Nivolumab
- Where
- 6 sites in United States
- Volunteers
- 100 people
- Sponsor
- Dana-Farber Cancer Institute
Prostatic Neoplasms
Vaccine and Antibody Treatment of Prostate Cancer
This study will evaluate the side effects of a fixed dose of vaccine and GM-CSF with increasing doses of anti-CTLA-4 antibody in patients with advanced prostate cancer.
- Trial name
- NCT00113984
- Testing
- PROSTVAC-V/TRICOM, PROSTVAC-F/TRICOM, MDX-010
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Study On Lidocaine Vs. Placebo Pain Control During Transrectal Ultrasound Guided Prostate Biopsy
Patients at risk for having prostate cancer usually undergo a biopsy of their prostate. This is most often done in the private urology office.
- Trial name
- NCT00441532
- Testing
- Lidocaine
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Corewell Health East
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.